Integrin peptide yields positive outcomes for VMA, VMT in phase II trial: dual mechanisms of action appear to inhibit new blood vessel formation, reduce leakage.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Connect Read More Add to Saved list